—各奖项申报陆续启动,欢迎关注—2025年ADA大会为内分泌代谢疾病领域的热度再添一把火,最为热门的GLP-1赛道竞争已进入白热化,全球药企不断加码双靶点、三靶点药物,品种越来越丰富,技术迭代持续加速。与此同时,本土企业正在加速追赶,在这个人人都在争抢的赛道,谁都渴望成为“中国版礼来或者诺和诺德”。而在众多参与者之中,一个隐藏的代谢巨头正在崛起——东阳光药正以GLP-1多靶点激动剂为关键锚点,构建...
Source Link—各奖项申报陆续启动,欢迎关注—2025年ADA大会为内分泌代谢疾病领域的热度再添一把火,最为热门的GLP-1赛道竞争已进入白热化,全球药企不断加码双靶点、三靶点药物,品种越来越丰富,技术迭代持续加速。与此同时,本土企业正在加速追赶,在这个人人都在争抢的赛道,谁都渴望成为“中国版礼来或者诺和诺德”。而在众多参与者之中,一个隐藏的代谢巨头正在崛起——东阳光药正以GLP-1多靶点激动剂为关键锚点,构建...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.